Annals of Surgical Oncology

, Volume 20, Issue 6, pp 1993–1999 | Cite as

Neoadjuvant Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer in a Single High-Volume Center

  • A. Zanoni
  • G. Verlato
  • S. Giacopuzzi
  • J. Weindelmayer
  • F. Casella
  • F. Pasini
  • E. Zhao
  • G. de Manzoni
Gastrointestinal Oncology



Neoadjuvant chemoradiotherapy (CRT) is now considered the standard of care by many centers in the treatment of both squamous cell carcinoma (SCC) and adenocarcinoma of the esophagus. This study evaluates the effectiveness of a neoadjuvant CRT protocol, as regards pathological complete response (pCR) rate and long-term survival.


From 2003 to 2011, at Upper G.I. Surgery Division of Verona University, 155 consecutive patients with locally advanced esophageal cancers (90 SCC, 65 adenocarcinoma) were treated with a single protocol of neoadjuvant CRT (docetaxel, cisplatin, and 5-fluorouracil with 50.4 Gy of concurrent radiotherapy). Response to CRT was evaluated through percentage of pathological complete response (pCR or ypT0N0), overall (OS) and disease-related survival (DRS), and pattern of relapse.


One hundred thirty-one patients (84.5 %) underwent surgery. Radical resection (R0) was achieved in 123 patients (79.3 %), and pCR in 65 (41.9 %). Postoperative mortality was 0.7 % (one case). Five-year OS and DRS were respectively 43 and 49 % in the entire cohort, 52 and 59 % in R0 cases, and 72 and 81 % in pCR cases. Survival did not significantly differ between SCC and adenocarcinoma, except for pCR cases. Forty-nine patients suffered from relapse, which was mainly systemic in adenocarcinoma. Only three out of 26 pCR patients with previous adenocarcinoma developed relapse, always systemic.


This study suggests that patients treated with the present protocol achieve good survival and high pCR rate. Further research is necessary to evaluate whether surgery on demand is feasible in selected patients, such as pCR patients with adenocarcinoma.


Conflict of interest

The authors declared no conflicts of interest.


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, CA Cancer J Clin. 2012;62(1):10–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Berrino F, De Angelis R, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007;8(9):773–783.Google Scholar
  3. 3.
    Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8(3):226–234.PubMedCrossRefGoogle Scholar
  4. 4.
    Lv J, Cao XF, Zhu B, Ji L, Tao L, Wang DD. Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol. 2009;15(39):4962–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92.PubMedCrossRefGoogle Scholar
  6. 6.
    Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185(6):538–43.PubMedCrossRefGoogle Scholar
  7. 7.
    van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.PubMedCrossRefGoogle Scholar
  8. 8.
    Verlato G, Zanoni A, Tomezzoli A, et al. Response to induction therapy in oesophageal and cardia carcinoma using Mandard tumour regression grade or size of residual foci. Br J Surg. 2010;97(5):719–25.PubMedCrossRefGoogle Scholar
  9. 9.
    Pasini F, de Manzoni G, Pedrazzani C, et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol. Jul 2005;16(7):1133–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Marubini E, Valsecchi M. Analysing survival data from clinical trials and observational studies. Chichester: Wiley; 1995.Google Scholar
  11. 11.
    Kranzfelder M, Buchler P, Lange K, Friess H. Treatment options for squamous cell cancer of the esophagus: a systematic review of the literature. J Am Coll Surg. 2010;210(3):351–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8(6):545–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Samalin E, Ychou M. Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts? Curr Opin Oncol. 2007;19(4):384–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011;47(3):354–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 20 2009;27(6):851–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Dimick JB, Pronovost PJ, Cowan JA, Lipsett PA. Surgical volume and quality of care for esophageal resection: do high-volume hospitals have fewer complications? Ann Thorac Surg. 2003;75(2):337–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Metzger R, Bollschweiler E, Vallbohmer D, Maish M, DeMeester TR, Holscher AH. High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality? Dis Esophagus. 2004;17(4):310–14.PubMedCrossRefGoogle Scholar
  18. 18.
    Wenner J, Zilling T, Bladstrom A, Alvegard TA. The influence of surgical volume on hospital mortality and 5-year survival for carcinoma of the oesophagus and gastric cardia. Anticancer Res. 2005;25(1B):419–24.Google Scholar
  19. 19.
    Choong NW, Mauer AM, Haraf DC, et al. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol. 2011;28(Suppl 1):S152–61.PubMedCrossRefGoogle Scholar
  20. 20.
    Knox JJ, Wong R, Visbal AL, et al. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer. 2010;116(17):4023–32.PubMedCrossRefGoogle Scholar
  21. 21.
    Koo DH, Park SI, Kim YH, et al. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Cancer Chemother Pharmacol. 2012;69(3):655–63.PubMedCrossRefGoogle Scholar
  22. 22.
    Pera M, Gallego R, Montagut C, et al. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol. 2012;23(3):664–70.PubMedCrossRefGoogle Scholar
  23. 23.
    Spigel DR, Greco FA, Meluch AA, et al. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 2010;28(13):2213–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20(2):231–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Koshy M, Greenwald BD, Hausner P, et al. Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns. Am J Clin Oncol. 2011;34(3):259–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Courrech Staal EF, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg. 2010;97(10):1482–96.Google Scholar
  27. 27.
    Meguid RA, Hooker CM, Taylor JT, et al. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg. 2009;138(6):1309–17.PubMedCrossRefGoogle Scholar
  28. 28.
    Rohatgi PR, Swisher SG, Correa AM, et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005;104(7):1349–55.PubMedCrossRefGoogle Scholar
  29. 29.
    Vallbohmer D, Holscher AH, DeMeester S, et al. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010;252(5):744–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Orditura M, Galizia G, Morgillo F, et al. Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials. Dis Esophagus. 2012;25(2):130–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Park JW, Kim JH, Choi EK, et al. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011;81(3):691–697.PubMedCrossRefGoogle Scholar
  32. 32.
    Scheer RV, Fakiris AJ, Johnstone PA. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer. Int J Radiat Oncol Biol Phys. 2011;80(4):996–1001.PubMedCrossRefGoogle Scholar
  33. 33.
    Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Gardner-Thorpe J, Hardwick RH, Dwerryhouse SJ. Salvage oesophagectomy after local failure of definitive chemoradiotherapy. Brit J Surg. 2007;94(9):1059–66.PubMedCrossRefGoogle Scholar
  36. 36.
    Dittrick GW, Weber JM, Shridhar R, et al. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy. Ann Surg Oncol. 2012;19(5):1678–84.PubMedCrossRefGoogle Scholar
  37. 37.
    Bradbury PA, Kulke MH, Heist RS, et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics. 2009;19(8):613–25.PubMedCrossRefGoogle Scholar
  38. 38.
    Fareed KR, Kaye P, Soomro IN, et al. Biomarkers of response to therapy in oesophago-gastric cancer. Gut. 2009;58(1):127–43.PubMedCrossRefGoogle Scholar
  39. 39.
    Warnecke-Eberz U, Metzger R, Bollschweiler E, et al. TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics. 2010;11(1):55–64.PubMedCrossRefGoogle Scholar
  40. 40.
    Wu X, Gu J, Wu TT, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 10 2006;24(23):3789–98.PubMedCrossRefGoogle Scholar
  41. 41.
    Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8(9):797–805.PubMedCrossRefGoogle Scholar
  42. 42.
    Piessen G, Briez N, Triboulet JP, Mariette C. Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery? Ann Surg Oncol. 2007;14(7):2036–44.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • A. Zanoni
    • 1
  • G. Verlato
    • 2
  • S. Giacopuzzi
    • 1
  • J. Weindelmayer
    • 1
  • F. Casella
    • 1
  • F. Pasini
    • 3
  • E. Zhao
    • 4
  • G. de Manzoni
    • 1
  1. 1.Upper G.I. Surgery DivisionUniversity of VeronaVeronaItaly
  2. 2.Unit of Epidemiology and Medical StatisticsUniversity of VeronaVeronaItaly
  3. 3.Division of OncologyRovigo HospitalRovigoItaly
  4. 4.Department of General Surgery, Renji HospitalShangai Jiaotong UniversityShanghaiChina

Personalised recommendations